ARCHIVES

ODAC Unanimously Rejects Melblez, Citing Lower Survival

This article is from The Cancer Letter archive.

Vol. 39 No. 20 | May 17, 2013

Download PDF Visit The Full Archive

Related Articles

IND-Exempt Trials May Need Special Review, HCFA Says.

September 29, 2000

Treatment IND or GM-CSF Is Approved

October 5, 1990

ACS President & COO Resigns Unexpectedly; Was Seen as Contender for CEO Position

December 19, 2014

Oncologists Don’t Demand Increased Survival When Ordering Expensive Drugs, Survey Finds

April 13, 2012

Drug Marketing; Zeneca sues Eli Lilly, Claiming Misleading Promotion of Evista

March 12, 1999

International Cancer Genome Consortium Aims To Produce Data On 50 Cancer Types.

May 2, 2008